Skip to main content
. Author manuscript; available in PMC: 2012 Aug 18.
Published in final edited form as: Nanomedicine (Lond). 2012 Jan;7(1):65–78. doi: 10.2217/nnm.11.93

Figure 6. Doxorubicin cytotoxicity in resistant MCF-7 cells after treatment with phosphoethanolamine-polyethylenimine complexes at different time lags (h).

Figure 6

MCF-7 resistant and sensitive cells were treated with formulations prepared with siRNA targeting MDR-1 (siMDR-1). Control cells were treated with medium. At different time points post-siMDR-1, cells were treated with doxorubicin (1 µg/ml) for 72 h, and viability was measured. Data are expressed as the mean ± standard deviation (n = 3). p < 0.001 for dioleoylphosphatidylethanolamine-polyethylenimine treatments versus Dox-only treated cells, for all time-points.

Dox: Doxorubicin.